VSY Biotechnology Launches Enova, the First 100% Glistening Free

Hydrophobic Acrylic IOL that does not Require Pre-hydration and Storage in Saline Solution!

VSY Biotechnology announces Enova, the first 100% glistening-free hydrophobic acrylic IOL that requires neither pre-hydration nor storage in saline. Enova is packaged dry and has excellent optical and mechanical properties.

Leinfelden-Echterdingen, Germany July 22, 2020 ­- VSY Biotechnology GmbH,

Willkommen in Deutschland! VSY Biotechnology moves its HQ to Germany

VSY Biotechnology announced that it is moving its headquarters from the Netherlands to Germany. VSY Biotechnology GmbH will be the company’s new headquarters.

VSY Biotechnology commenced operations in the late 90s. Since then, the company has achieved several milestones on the way to becoming a global player in the innovation-driven medical device sector.

Countdown to the Ophthalmology Star Awards

Applications for this year’s Ophthalmology Star Awards (OSA), organized annually by VSY Biotechnology, will continue until July 15, 2020.

As part of the Ophthalmology Star Awards (OSA), articles by ophthalmologists published in English since January 2019 are being evaluated by an international jury. Ophthalmologists can apply for the contest until July 15, 2020,

A New Drug to Treat COVID-19: TR-C 19 at Human Testing Phase

VSY Biotechnology Research Center has developed a strong R&D program in various areas of biotechnology and is now proud to announce its latest achievement: TR-C 19, a drug to treat COVID-19.

At VSY Biotechnology, we are very excited to announce that a new drug, named TR-C 19, has been developed to treat COVID-19 by the VSY Biotechnology R&D team.

Dr. Fatih Ergin, CEO of VSY Biotechnology: “The 21st century has started just now”

Dr. Fatih Ergin, CEO of VSY Biotechnology, stated that traditional roles and models worldwide will be completely transformed by the traumatic impact of the coronavirus and added that “the 21st century has just started now.”

Dr. Fatih Ergin, CEO of VSY Biotechnology, stated that the company anticipates that the coronavirus pandemic, which has led to many losses of life,

Acriva Trinova Has Been Registered by The European Patent Office

World’s First and Only Sinusoidal Trifocal Optical Designed Intraocular Lens Acriva Trinova has Been Registered by the Euroepean Patent Office

European Patent Office (EPO) has issued the decision of appropriate for patent for world’s first and only intraocular lens produced with Sinusoidal Vision Technology (SVT) by VSY Biotechnology.

In the year 2018,

VSY Biotechnology Picks the Stars of Ophthalmology

With its booth, and scientific and social events, VSY Biotechnology was the center of attention at the 37th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), the world’s premier ophthalmology event. VSY Biotechnology organized the Stars of Ophthalmology Award Ceremony, presented the awards to the finalists, and attracted a great deal of attention in Paris on September 14–18,

VSY Biotechnology’s invention has been registered by the European Patent Institute

VSY Biotechnology’s invention, the Rotaryjet Preloaded Injector containing an accessory system for the storage and injection of an intraocular lens, has been registered by the European Patent Institute (EPI). This newly patented technology minimises the use of viscoelastic material in intraocular lens implantation and provides ultimate ease of use.

The Rotaryjet Preloaded Injector,

Halo and glare? Not a problem anymore!

ESCRS Board Member Prof.Dr. Ewa Mrukwa-Kominek told that Acriva Trinova implanted patients do not experience glare and halos and have very sharp visual equity.

Halos are bright circles that surround a light source, like headlights. Glare is light that enters your eye and interferes with your vision. These vision problems can be very disturbing even disabling after a cataract surgery.

START TYPING AND PRESS ENTER TO SEARCH